Relay Therapeutics Inc (RLAY) Reports Full Year 2023 Financial Results and Corporate Highlights [Yahoo! Finance]
Relay Therapeutics, Inc. (RLAY)
Company Research
Source: Yahoo! Finance
Revenue Growth : Full year 2023 revenue increased to $25.5 million, up from $1.4 million in 2022. R&D Expenses : Research and development expenses rose to $330.0 million for the full year 2023, compared to $246.4 million in 2022. G&A Expenses : General and administrative expenses increased to $75.0 million for the full year 2023 from $66.0 million in 2022. Net Loss : Net loss widened to $342.0 million for the full year 2023, or $2.79 per share, from $290.5 million, or $2.59 per share in 2022. Warning! GuruFocus has detected 2 Warning Sign with RLAY. On February 22, 2024, Relay Therapeutics Inc ( NASDAQ:RLAY ) released its 8-K filing , detailing the fourth quarter and full year 2023 financial results and corporate highlights. As a clinical-stage precision medicine company leveraging its Dynamo platform to revolutionize drug discovery, Relay Therapeutics Inc ( NASDAQ:RLAY ) is focused on advancing a pipeline of medicine candidates targeting precision oncology and genetic dise
Show less
Read more
Impact Snapshot
Event Time:
RLAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLAY alerts
High impacting Relay Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLAY
News
- Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024GlobeNewswire
- Relay Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- Relay Therapeutics: Platform More Important Than Programs [Seeking Alpha]Seeking Alpha
- Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.MarketBeat
- Relay Therapeutics to Participate in Three Upcoming Investor ConferencesGlobeNewswire
RLAY
Earnings
- 2/22/24 - Beat
RLAY
Analyst Actions
- 2/22/24 - Stifel
RLAY
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- RLAY's page on the SEC website